['type 2 diabetes mellitus']
['medi0382', 'placebo']

        Inclusion Criteria:

          -  Diagnosis of T2DM

          -  Must provide written informed consent

          -  Body mass index greater than (>) 27 and less than (<) 40 kg/m^2, inclusive

          -  Venous access suitable for multiple cannulations

          -  Vital signs within normal specified ranges

          -  Females must be non-lactating and non-childbearing potential

          -  Males must practice 2 effective contraceptive measures if sexually active

        Exclusion Criteria:

          -  Any concurrent condition that in the opinion of the investigator would interfere with
             the evaluation of the investigational product

          -  History or presence of gastrointestinal, renal, or hepatic disease or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs

          -  History of cancer within the last 10 years, with the exception of non-melanoma skin
             cancer

          -  Any clinically important illness (except for T2DM), medical/surgical procedure, or
             trauma within 4 weeks prior to dosing

          -  Fasting glucose greater than or equal to (>=) 200 mg/dL

          -  Positive Hepatitis B, Hepatitis C or human immunodeficiency virus test or use of
             antiretroviral medications at screening.

          -  Concurrent or previous use of a glucagon-like peptide 1 receptor agonist

          -  Current or previous use of systemic corticosteroids within the past 28 days prior to
             screening

          -  Use of any medicinal products or herbal preparations licensed for control of body
             weight or appetite is prohibited.

          -  Known or suspected history of alcohol or drug abuse within the past 3 years.

          -  Positive drug screen
      